included OS, safety and quality-of-life. Study stratifies patients into two cohorts according to relapse-timing (within or over 3 months) from end of first-line chemotherapy. Result: From January 2016 to data cutoff, on 30th March 2018, 197 patients have been evaluated: 30 were registered as screening failures, mainly for contraindications to nintedanib use. The 167 patients considered in this preliminary analysis had a median age of 63.4 years (range 35-86), were predominantly male (68.9%), smokers or former-smokers (84.4%) and with ECOG-performance status 0 (72.5%). According to investigator's choice, 82 patients have been treated with T1 docetaxel (49.1%), 85 (50.9%) with T2 docetaxel (median docetaxel treatment 3.5 and 3.7 21-days cycles, respectively). No significant differences in median PFS have been observed between T1 and T2 (3.83 vs 4.32 months, respectively; HR 0.889 [95% IC 0.598-1.321], p-value¼0.559). After a median follow-up of 7.28 months (standard deviation¼5.55), a trend of similar OS has emerged in both T1 and T2 (6.63 vs 7.91 months, respectively; HR 0.770 [95% IC 0.484-1.225], p-value¼0.270). Survival data of relapsetiming cohorts are not yet mature. Commonest toxicities in T1 and T2 were: fatigue (53.6% vs 65.9%, respectively), diarrhea (50.0% vs 47.0%), afebrile neutropenia (13.4% vs 52.9%) and ALT elevation (29.3% vs 20.0%). Conclusion: The SENECA trial is a real-life Italian experience, whose preliminary results confirm the efficacy and safety of second-line treatment with nintedanib and docetaxel for nsNSCLC patients, regardless from docetaxel schedule, suggesting higher toxicities for docetaxel q3wks.
included OS, safety and quality-of-life. Study stratifies patients into two cohorts according to relapse-timing (within or over 3 months) from end of first-line chemotherapy. Result: From January 2016 to data cutoff, on 30th March 2018, 197 patients have been evaluated: 30 were registered as screening failures, mainly for contraindications to nintedanib use. The 167 patients considered in this preliminary analysis had a median age of 63.4 years (range 35-86), were predominantly male (68.9%), smokers or former-smokers (84.4%) and with ECOG-performance status 0 (72.5%). According to investigator's choice, 82 patients have been treated with T1 docetaxel (49.1%), 85 (50.9%) with T2 docetaxel (median docetaxel treatment 3.5 and 3.7 21-days cycles, respectively). No significant differences in median PFS have been observed between T1 and T2 (3.83 vs 4.32 months, respectively; HR 0.889 [95% IC 0.598-1.321], p-value¼0.559). After a median follow-up of 7.28 months (standard deviation¼5.55), a trend of similar OS has emerged in both T1 and T2 (6.63 vs 7.91 months, respectively; HR 0.770 [95% IC 0.484-1.225], p-value¼0.270). Survival data of relapsetiming cohorts are not yet mature. Commonest toxicities in T1 and T2 were: fatigue (53.6% vs 65.9%, respectively), diarrhea (50.0% vs 47.0%), afebrile neutropenia (13.4% vs 52.9%) and ALT elevation (29.3% vs 20.0%). Conclusion: The SENECA trial is a real-life Italian experience, whose preliminary results confirm the efficacy and safety of second-line treatment with nintedanib and docetaxel for nsNSCLC patients, regardless from docetaxel schedule, suggesting higher toxicities for docetaxel q3wks. Background: MET exon 14 (METex14) alterations are targetable drivers found in 3-4% of lung cancers. The frequency of intracranial disease and patterns of central nervous system (CNS) progression on MET tyrosine kinase inhibitors (TKI) are not well characterized. Method: Patients with advanced METex14-altered lung cancers identified by next-generation sequencing (MSK-IMPACT) between January 2014 and March 2018 were eligible for analysis. A retrospective review of clinical features, patterns of metastases, and CNS progression on MET-TKI was performed. The frequency of intracranial disease was compared to cohorts single-center of EGFR-mutant (n¼200), ERBB2-mutant (n¼98) and KRAS-mutant (n¼200) lung cancers. Result: 82 patients with metastatic METex14-altered lung cancers were identified. The median age was 73; 56% (n¼46) were female and 54% (n¼44) were former smokers. The frequency of brain metastases at baseline was 11% (n¼9/82). The lifetime frequency of intracranial metastases from diagnosis of metastatic disease was 34% (n¼28/82). By comparison, the frequency of brain metastases was 47% (94/200, p¼0.05) with EGFR-, 47% (46/98), p¼0.09) with ERBB2-, and 32% (64/200, p¼0.78) with KRAS-driven tumors. 6% (n¼5/82) of patients developed leptomeningeal disease. The overall survival (OS) of patients who developed intracranial disease on therapy compared to those who did not develop intracranial disease was not significantly different (HR 0.66, 95% CI 0.30-1.43, p¼0.29). 51 patients received crizotinib, 26 of whom developed progressive disease. The frequency of intracranial (alone), intracranial and extracranial, and extracranial (alone) progression was 8% (2/26), 19% (5/26), and 73% (19/26), respectively. Conclusion: A third of patients with METex14-altered lung cancers develop intracranial disease. This proportion is lower than that seen in EGFR-and ERBB2mutant lung cancers and comparable to KRAS-mutant lung cancers. The frequency of CNS failure on crizotinib was lower than expected compared to historical rates in ALK-rearranged lung cancers. Background: Liquid biopsy for circulating tumor DNA (ctDNA) has been increasingly adopted for the detection of oncogenic drivers and drug resistance mechanisms. Practice guidelines for liquid biopsy are lacking and biologic factors influencing ctDNA detection and shedding are poorly understood. We evaluated factors influencing ctDNA detection, using EGFR-T790M as a case-study, in patients with acquired resistance to first/second-generation EGFR tyrosine kinase inhibitors (EGFR-TKI). Method: This single-center study included metastatic sensitizing EGFR-mutant lung cancer patients (exon 19 deletions, L858R, G719) who underwent plasma EGFR-T790M testing after acquired resistance to erlotinib, gefitinib, or afatinib between January 2016 and August 2017. Plasma T790M was performed by digital PCR. Variant allele fraction (VAF) was calculated as mutant/(wild-type+mutant) allele. Concordance between plasma and tissue testing was examined if tissue analysis (MSK-IMPACT and/or targeted PCR) occurred within 90 days of blood draw. Turnaround time (TAT) was measured from date of blood draw and/or biopsy to result. ctDNA results were correlated with metastatic site and the number of organs involved. Result: 177 patients underwent plasma T790M testing; 65% female, 47% current/former smokers. Plasma T790M was positive in 32% (56/177) of patients, tissue testing was T790M-positive in 46% (45/97), and overall T790M-positivity by either platform was 49% (86/177). The median TAT was shorter for plasma T790M compared to tissue PCR (9 vs 15 days, p<0.0001), and led to osimertinib use in 84% (47/56) of positive patients. Concordance between plasma and tissue T790M was 80% (32/40). 15 patients with positive plasma had matched tissue, 87% (13/15) were concordant on tissue. 76% (19/25) of the patients that were T790M-negative on plasma also tested negative on tissue. Median plasma T790M-VAF was 0.98% (range 0.1e49.5%), lower than tissue T790M-VAF (12.8%, range 2.58e27.8, p<0.0001). Plasma T790M-VAF did not correlate with time on osimertinib (p¼0.72). Plasma T790M status correlated with a higher number of metastatic sites (4 vs 3, p<0.0001). Plasma T790M detection by organ sites were: pleura (58% with metastases vs 34% without metastases, p¼0.14), bone (80% vs 21%, p¼0.0002), hepatic (61% vs 41%, p¼0.28), nodal (61% vs 33%, p¼0.07), adrenal (64% vs 44%, p¼0.60), brain (71% vs 38%, p¼0.08), and bone/hepatic concurrently (94% vs 98%, p¼0.04). Conclusion: Using plasma T790M as an archetypal example, cfDNA testing showed concordance and a shorter turnaround compared to tissue testing. cfDNA was more likely to result positive in patients with more metastatic sites, or osseous and hepatic metastases possibly driven by increased ctDNA shedding. The efficacy of platinum-based doublets, long the standard firstline treatments, has plateaued, with ORR¼30%. Anti-tumor synergy between gemcitabine and albumin-bound paclitaxel (ABP) was demonstrated by Frese et al. who showed that ABP downregulates cytidine deaminase, leading to increased intratumoral gemcitabine (Cancer Disc 2012). Based on these data, we sought to assess the efficacy of ABP + gemcitabine in patients with SQCLC. Method: This was a Simon two-stage phase 2 study of ABP + gemcitabine in chemotherapy-naïve, PD-L1 low/unknown advanced SQCLC patients (NCT02525653). Primary endpoint: best ORR. H0¼25% (6/17 responses) and HA¼45% (16/41 responses). ABP (100mg/m 2 ) + gemcitabine (1000mg/m 2 ) was initially given on D1, D8, D15 of an every 4 week cycle for up to 6 cycles (A1). After clearing H0, the study was amended to a 3 week cycle (D1, D8 treatment) and to allow maintenance ABP after C4 (A2). All patients underwent NGS by MSK-IMPACT. Result: N¼27 patients were evaluable for the primary endpoint. Median age¼70, age 70¼60%, female¼30%, median KPS¼80%, smokers¼93%. 46% of patients had PD-L1 IHC <50% (0-20%). 54% were PD-L1 unknown. Grade 3 related AEs included: fatigue-13%, neuropathy-4%; diarrhea-4%; lung infection-4%, anemia-9%; decreased platelet count-4%, and decreased neutrophils (4%). Four patients (17%) experienced related SAEs including, separately, G3 febrile neutropenia, G3 WBC decrease, G3 thrombocytopenia, and G3 anemia. ORR for the entire cohort was 63% (Figure 1) . ORR in A2¼ 71% (10/14). 8 patients in A1 had dose modifications resulting in equivalency to the A2 schedule. ORR in the A2+A1 dose modified cohort¼73% (16/22), meeting the primary endpoint early. Median PFS¼8mo; OS not yet mature. Conclusion: ABP + gemcitabine is an effective and welltolerated regimen in patients with untreated advanced SQCLC with a response rate exceeding that associated with platinum regimens and first-line immunotherapy. Background: Osimertinib is a potent, irreversible third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) for both EGFR activating and T790M resistant mutation. In this trial, the treatment efficacy of osimertinib was assessed in previously untreated patients with advanced or metastatic non-small cell lung carcinoma (NSCLC) harboring the EGFR activating mutation, which was detected from circulating tumor DNA (ctDNA) combined with tumor genotyping. Method: Venous blood sampling was performed from the patients with EGFR activating mutation confirmed by tissue genotyping. To extract ctDNA from the plasma, 15 mL of peripheral blood was withdrawn and centrifuged, immediately before storage. Cobas TM v2 and PANA Mutyper TM were used for ctDNA genotyping. Patients with the EGFR activating mutation, detected from ctDNA, were enrolled and received a once-daily administration of osimertinib, 80 mg. The primary endpoint was objective response rate (ORR), and secondary endpoints were ctDNA test sensitivity, progression-free survival (PFS), duration of response (DoR), and safety of osimertinib treatment (ClinicalTrials.gov, Identifier: NCT02769286). Result: Thirty-nine patients with activating EGFR mutations in tumor genotyping were screened from February 2017, and the enrollment of the last patient was completed in March 2018. The ctDNA of 29 patients was positive for activating EGFR mutation, and 19 patients were enrolled (exon 19 deletion, n¼11; L858R or L861Q, n¼7; G719A, n¼1). Median age was 70 years (range 32-84) and the majority of patients had brain metastasis (15/19, 78.9%). In the responseevaluable population (n¼17), ORR was 64.7% (11/17) and DCR was 94.1% (16/17). According to EGFR mutation type of tumor genotyping, patients with exon 19 deletion showed more favorable ORR (8/9, 88.9%) than patients with exon 21 L858R/L861Q (3/7, 42.9%). In patients evaluable for CNS response (n¼14), DCR of brain metastasis was 100.0% (14/14). The sensitivity of the ctDNA tests for activating EGFR mutation was 74.4% when using both tests, and 61.5% (Mutyper) or 64.1% (Cobas V2) with either test. Only one patient experienced drug-related interstitial pneumonia of grades 3 and resulted in drug discontinuation. Survival data including PFS was not matured (2/19, 10.5%) and the analysis will be followed. Conclusion: Osimertinib had favorable efficacy in first-line treatment of NSCLC harboring the EGFR activating mutation, detected from ctDNA combined with tumor genotyping, even though in patients with old age and brain metastasis. Keywords: osimertinib, ctDNA, non-small cell lung cancer P1.01-78 The Incidence of Brain Metastases in ROS1-Rearranged Non-Small Cell Lung Cancer at Diagnosis and Following Progression on Crizotinib
